ModeX Therapeutics, Inc.
https://modextherapeutics.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ModeX Therapeutics, Inc.
Dealmaking Quarterly Statistics, Q2 2022
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Preparing for COVID 2.0: Understanding Animal ‘Spillover’ And Addressing Excessive Nationalism
Former Merck executive Julie Gerberding, Biocon chief Kiran Mazumdar-Shaw, ModeX Therapeutics’ John Mascola, and NIH’s Larry Tabak discuss what it will take to better handle the next pandemic.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ModeX Therapeutics, Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice